Agios Pharmaceuticals Shares Down 10.7% After Insider Selling (AGIO)
Agios Pharmaceuticals (NASDAQ:AGIO) traded down 10.7% during mid-day trading on Monday following insider selling activity, Analyst RN reports. The stock traded as low as $44.18 and last traded at $44.21, with a volume of 459,235 shares traded. The stock had previously closed at $49.50.
Specifically, Insider Scott Biller sold 2,004 shares of Agios Pharmaceuticals stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $50.05, for a total transaction of $100,300.20. The sale was disclosed in a filing with the SEC, which is available at this link.
Several analysts have recently commented on the stock. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 16th. They now have a $60.00 price target on the stock, up previously from $55.00. Separately, analysts at Zacks upgraded shares of Agios Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Tuesday, May 6th. They now have a $44.80 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Agios Pharmaceuticals from $51.00 to $65.00 in a research note on Monday, April 7th. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. Agios Pharmaceuticals presently has an average rating of “Buy” and an average price target of $51.70.
The stock has a 50-day moving average of $39.35 and a 200-day moving average of $34.96. The company’s market cap is $1.495 billion.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.01. Analysts expect that Agios Pharmaceuticals will post $-1.47 EPS for the current fiscal year.
Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company’s ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (NASDAQ:AGIO) are treated.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.